Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6143062 | 0.90 | CYP19A1 (0.63) | CYP19A1ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL6142614 | 0.83 | CYP19A1 (0.49) | CYP19A1ALOX15ALOX12 | |
| SCHEMBL242978 | 0.79 | CYP19A1 (0.61) | CYP19A1ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL2070571 | 0.79 | CYP19A1 (0.61) | CYP19A1ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL6142591 | 0.77 | ALOX12 (0.49) | CYP19A1ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL22339915 | 0.77 | CYP19A1 (0.60) | CYP19A1ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL19410272 | 0.77 | CYP19A1 (0.62) | CYP19A1ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL10685626 | 0.77 | CYP19A1 (0.69) | CYP19A1ALOX15ALOX12 | |
| SCHEMBL30251185 | 0.77 | CYP19A1 (0.69) | CYP19A1ALOX15ALOX12 | |
| SCHEMBL4432673 | 0.75 | CYP19A1 (0.56) | CYP19A1ALOX15ALOX12KCNH2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951883-B2 | 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2005-10-04 | — | — | US | disclosed |
| EP-1355906-B1 | 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CHIESI FARMA SPA (IT) | 2005-01-12 | — | — | EP | disclosed |
| US-20040106595-A1 | 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-06-03 | — | — | US | disclosed |
| EP-1355906-A1 | 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.p.A. (IT) | 2003-10-29 | — | — | EP | disclosed |
| EP-1229036-A1 | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | CHIESI FARMACEUTICI S.p.A. (IT) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002059113-A1 | 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106595-A1 | 2H-1-benzopyran derivatives processes for their preparation and pharmaceutical compositions thereof | CYP19A1, BRCA1, HPD | CYP19A1 1/4885ALOX15 420/4885ALOX12 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.